DOCSLIB.ORG

Injectable Contraceptives: Tools for Providers Ore Than Twice As Many Women Are Using Minjectable Contraceptives Today As a Decade Ago, and the Numbers Keep Growing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Injectable Contraceptives: Tools for Providers ore than twice as many women are using Minjectable contraceptives today as a decade ago, and the numbers keep growing. Women choose injectables because they are highly effective, long-acting, reversible, and private. At the same time many women do not choose injectables or stop using them because of side INFO Project effects—particularly irregular bleeding, no Center for Communication monthly bleeding, and weight gain—or because Programs they have trouble returning for injections (13, 70, 135, 168). Family planning programs are meeting increasing demand while helping providers to maintain good quality of care. Attention to quality, and to counseling especially, can be the difference between successful and unsuccessful efforts to expand access to injectables (77, 78). Using the tools in this INFO Reports, providers can inform women about injectables and help them be satisfi ed users. Table 1. Formulations and Injection Schedules of Injectable Contraceptives Common Trade Names Formulation Injection Type and Schedule Coming Soon: Progestin-Only Injectables “Injectables Toolkit” ® ® Web site. Go to www. Depo-Provera , Megestron , Depot medroxyprogesterone acetate One intramuscular (IM) injection Contracep®, Depo-Prodasone® (DMPA) 150 mg every 3 months injectablestoolkit.org for job aids One subcutaneous injection every depo-subQ provera 104® (DMPA-SC) DMPA 104 mg and information 3 months about injectable Norethisterone enanthate (NET-EN) Noristerat®, Norigest®, Doryxas® One IM injection every 2 months contraceptives 200 mg Combined Injectables (progestin + estrogen)1 Medroxyprogesterone acetate 25 mg + Cyclofem®, Ciclofeminina®, Lunelle® 2 One IM injection every month Estradiol cypionate 5 mg (MPA/E2C) NET-EN 50 mg + Estradiol valerate Mesigyna®, Norigynon® One IM injection every month 5 mg (NET-EN/E2V) Deladroxate®, Perlutal®, Dihydroxyprogesterone (algestone) Topasel®, Patectro®, Deproxone®, acetophenide 150 mg + Estradiol One IM injection every month Nomagest® enanthate 10 mg Dihydroxyprogesterone (algestone) Anafertin®, Yectames® acetophenide 75 mg + Estradiol One IM injection every month enanthate 5 mg Chinese Injectable No. 1® 17α-hydroxyprogesterone caproate One IM injection every month, 250 mg + Estradiol valerate 5 mg except 2 injections in fi rst month Sources: International Planned Parenthood Federation 2005 (83), Lande 1995 (99), Liggeri 2006 (103), WHO 1990 (204), WHO 1993 (205) 1Also called monthly injectables. 2The U.S. Food and Drug Administration approved Lunelle, but it is currently not available in the United States. See companion Population Reports, “Expanding Services for Injectables” December 2006 • Issue No. 8 205402_JHU-InfoReport.indd 1 12/12/06 10:52:44 AM Checklist for Giving Intramuscular How to Use This Report Family planning providers can use the checklists Contraceptive Injections and tables in this report to: Family planning providers can use this checklist to help ensure • Counsel about injectables or answer clients’ questions (see Table 2, pp. 3–4), that injections are safe. ˛ • Identify women who may not be able to use DMPA or NET-EN for medical reasons (see Prepare equipment and supplies Checklist, pp. 5–6), • Be reasonably sure that a woman is not preg- q In advance, assemble the supplies and materials needed nant before giving the fi rst injection (see Checklist, p. 6, questions 8–13), •Single-dose vial • Review the steps required to give an injection •Sterile needle and syringe (If auto-disable (AD) or conventional disposable safely (see Checklist, this page), and syringes and needles are not available, use sterile equipment designed • Help women be informed and satisfi ed con- for steam sterilization. Do not reuse disposable equipment.) tinuing users of injectables (see Table 3, p. 7). •Cotton wool This report accompanies Population Reports, “Expanding Services for Injectables”. q Wash hands with soap and water before giving the injection, if possible. Gloves See also Population Reports, “When are not needed unless there is a chance of direct contact with blood or other Contraceptives Change Monthly Bleeding,” Series J, No. 54, August 2006. body fl uids. q Inspect the vial and check expiry date. Discard any with visible cracks or leaks. This report was prepared by Robert Lande q With injectables containing DMPA, roll the vial back and forth or gently shake to and Catherine Richey, MPH. mix contents. If the vial of NET-EN is cold, warm to skin temperature before giving Ward Rinehart, Editor. Rafael Avila and Francine Mueller, Designers. the injection. The INFO Project appreciates the assistance Intramuscular injections can be given of the following reviewers: Jacob Adetunji, in the deltoid muscle of either arm Kim Best, Richard Blackburn, Marc G. or the left or right buttock (gluteal Boulay, Steve Brooke, Gloria Coe, María muscle, upper outer portion), del Carmen Cravioto, Juan Díaz, Maxine whichever the woman prefers.1 To Eber, Douglas Huber, Barbara Janowitz, minimize the risk of injury, providers Sophie Logez, Enriquito R. Lu, Kuhu Maitra, Kavita Nanda, Fredrick Ndede, Carib should take care to deliver the Nelson, Paula Nersesian, Gael O’Sullivan, injection in the proper site. Joseph F. Perz, James Phillips, Roberto Rivera, Ruwaida Salem, Hilary Schwandt, Give the injection safely Stephen Settimi, James D. Shelton, Jenni Smit, Cathy Solter, J. Joseph Speidel, Jeff Spieler, Tara M. Sullivan, Jagdish Upadhyay, q Explain the injection procedure to the client and point out that the syringe and Ushma Upadhyay, Marcel Vekemans, Irina Yacobson, and Vera Zlidar. needle are sterile. Suggested citation: Lande, R. and Richey, C. q Ask the client her preferred site for injection: upper arm (deltoid muscle) or “Injectable Contraceptives: Tools for Provid- buttocks (gluteal muscle). To decrease discomfort, position her so that her ers,” INFO Reports, No. 8. Baltimore, Johns Hopkins Bloomberg School of muscles are relaxed. Public Health, INFO Project, Dec. 2006. q Wash the injection site with soap and water if it is visibly dirty. Swabbing clean skin Available online: http://www.infoforhealth.org/inforeports/ or wiping the skin with antiseptic before giving an injection is not necessary. q Pierce the top of the vial with the sterile needle and fi ll syringe with the proper dose. q With a smooth, steady motion, insert the needle deep into the muscle at a right angle (90°) and inject the contents of the syringe. INFO Project Center for Communication Programs q After the injection ask the client to hold cotton wool on the injection site. Instruct Johns Hopkins Bloomberg School of Public Health the client not to massage the injection site. 111 Market Place, Suite 310 Baltimore, Maryland 21202 USA q Wash hands with soap and water after giving the injection, if possible. 410.659.6300 410.659.6266 (fax) www.infoforhealth.org Dispose of waste appropriately [email protected] Earle Lawrence, Project Director, INFO Project; Do not recap, bend, cut, or break needles after use. Discard the used disposable Stephen Goldstein, Chief, Publications Division; q Theresa Norton, Associate Editor; needle and syringe immediately in an enclosed sharps container. Linda Sadler, Production Manager. q If reusable syringes and needles are used, they must be sterilized again after INFO Reports is designed to provide an accurate and authoritative report on important developments each use. in family planning and related health issues. The opinions expressed herein are those of the authors q Seal and dispose of sharps containers when they are three-fourths full. and do not necessarily refl ect the views of the U.S. Follow program or clinic guidelines for proper waste management. Agency for International Development (USAID) or the Johns Hopkins University. Adapted from: Hutin 2003 (80) Published with support from USAID, Global, GH/POP/PEC, 1Intramuscular injection of the combined injectable Cyclofem can also be given in the thigh (lateral muscle of the quadriceps). under the terms of Grant No. GPH-A-00-02-00003-00. 2 205402_JHU-InfoReport.indd 2 12/12/06 10:57:31 AM 205402_JHU-InfoReport.indd TableChoiceofInjectableContraceptives2.HelpingClientsMakeaWell-Informed safetyandsideeffects,Effectiveness, acontraceptivemethod(27,55,227).Whentheyareseekthefactorsthatwomenconsidermostimportantwhenchoose familyplanningservices,mostwomenalreadyhaveamethodinmindthatintereststhem (198). Increasingly, thatmethodisaninjectablecontraceptive.Good -quality programsandknowshowitisused.Counselingalsohelpsaassuredofitssafety,sideeffects,ensurethatwomaninterestedinaninjectableunderstandseffectiveness 3 womanThisinformationtohelpwomenwiththeirdecisiontableoffersdecideifthemethodsuitsherneeds,preferences,andcurrentsituation. -making. Progestin-Only Injectables 1 Combined Injectables KEY POINTS:Givewomenthisinformation Womenneedthis •contraceptivemethods.Oneofthemosteffective •contraceptivemethods.Oneofthemosteffective information tomake •haveaninjectionevery3monthsforDMPAWomen Importantorevery2monthsforNET-EN. •haveaninjectiononceamonth.ImportanttoWomen an informedchoice totrybeontimeforthenextinjection. trytobeontimeforthenextinjection. about injectables • Mostwomenhavefrequentorirregularbleedingat first andthenlittleornomonthlybleeding. • tochangebleedingpatternsunpredictablyduringLikely Thisisnotharmful.Gradualweightgaincommonand the firstAfterThis3isnotharmful.monthsofuse. •take4monthslongeronaveragetobecomepregnantafterstoppingDMPAWomen thanafter monthsmostwomenhaveregularpatterns(around stoppingmethodsotherthaninjectables.
Recommended publications
  • Contraception: Choosing the Right Method for You

    Contraception: Choosing the Right Method for You

    Contraception: Choosing the Right Method for You Megan Sax, MD and James L. Whiteside, MD What’s available? Choosing a method of contraception can be overwhelming. The most commonly used methods of reversible contraception in the United States are: hormonal methods the intrauterine device (IUD) the implant barrier methods (e.g. male condom)1 Friends, family, and the Internet are full of stories of failed contraception or bad reactions and these stories can have a big influence that doesn’t always line up with the facts.2 However, knowing these facts is critical to figuring out what type will work best for you. Highly Effective Contraception The best place to start in choosing your contraception is to determine when, if ever, you are planning on starting a family. If you do not wish to become pregnant in the next year, a Long-Acting Reversible Contraceptive (LARC) device may be a good option. LARCs include an implant placed under the skin of the upper, inner arm (brand name Nexplanon) and the IUD. IUDs are placed inside the uterus (see Figure 1). They use copper (brand name ParaGard) or hormones (brand names: Mirena, Lilleta, Skyla, Kyleena) to stop a pregnancy from happening. LARCs are the most effective reversible form of contraception. Less than 1% of users experience unintended pregnancy during the first year of use.3 Currently, the implant Nexplanon is effective for 3 years. The hormonal IUD may be used for 3 to 5 years, depending on the brand. The copper IUD works for 10 years. These devices are inserted and removed by a medical care provider.
  • Sterilization and Abortion Policy Billing Instructions

    Sterilization and Abortion Policy Billing Instructions

    Sterilization and Abortion Policy Billing Instructions Table of contents Table of contents ...................................................................................................................................... 1 Hysterectomy ............................................................................................................................................ 2 Acknowledgement forms ..................................................................................................................... 2 Prior authorization requirements ......................................................................................................... 2 Covered services ................................................................................................................................... 2 Intrauterine Devices and Subdermal Implants ......................................................................................... 4 Family planning: sterilization .................................................................................................................... 4 Prior authorization requirements ......................................................................................................... 5 Covered services ................................................................................................................................... 5 Abortion .................................................................................................................................................... 6 Claim
  • F.8 Ethinylestradiol-Etonogestrel.Pdf

    F.8 Ethinylestradiol-Etonogestrel.Pdf

    General Items 1. Summary statement of the proposal for inclusion, change or deletion. Here within, please find the evidence to support the inclusion Ethinylestradiol/Etonogestrel Vaginal Ring in the World Health Organization’s Essential Medicines List (EML). Unintended pregnancy is regarded as a serious public health issue both in developed and developing countries and has received growing research and policy attention during last few decades (1). It is a major global concern due to its association with adverse physical, mental, social and economic outcomes. Developing countries account for approximately 99% of the global maternal deaths in 2015, with sub-Saharan Africa alone accounting for roughly 66% (2). Even though the incidence of unintended pregnancy has declined globally in the past decade, the rate of unintended pregnancy remains high, particularly in developing regions. (3) Regarding the use of contraceptive vaginal rings, updated bibliography (4,5,6) states that contraceptive vaginal rings (CVR) offer an effective contraceptive option, expanding the available choices of hormonal contraception. Ethinylestradiol/Etonogestrel Vaginal Ring is a non-biodegradable, flexible, transparent with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. Ethinylestradiol/Etonogestrel Vaginal Ring is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The main advantages of CVRs are their effectiveness (similar or slightly better than the pill), ease of use without the need of remembering a daily routine, user ability to control initiation and discontinuation, nearly constant release rate allowing for lower doses, greater bioavailability and good cycle control with the combined ring, in comparison with oral contraceptives.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
  • Hormonal Iuds Are Small ‘T- Shaped’ Plastic Devices That Are Inserted Into the Uterus (Womb)

    Hormonal Iuds Are Small ‘T- Shaped’ Plastic Devices That Are Inserted Into the Uterus (Womb)

    HORMONAL INTRAUTERINE DEVICES (IUDs) – (Mirena and Kyleena) What are the hormonal intrauterine devices (IUDs)? The hormonal IUDs are small ‘T- shaped’ plastic devices that are inserted into the uterus (womb). The hormonal IUDs contains progestogen. This is a synthetic version of the hormone progesterone made naturally by the ovaries. The hormonal IUDs have a coating (membrane) that controls the slow release of progestogen into the uterus. There are two different hormonal IUDs available in Australia. They are sold as Mirena and Kyleena. How effective are the hormonal IUDs? The hormonal IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 years. They can be used for contraception until 55 years of age if inserted when you are 45 years of age or older. How does the hormonal IUD work? IUDs affect the way sperm move and survive in the uterus (womb), stopping sperm from meeting and fertilising an egg. IUDs can also change the lining of the uterus, making it difficult for a fertilised egg to stick to the lining to start a pregnancy. The hormonal IUDs also work by thickening the fluid around the cervix (opening to the uterus/womb). This helps to prevent sperm from entering. Sometimes the hormonal IUDs can also stop the ovaries from releasing an egg. What are differences between Mirena and Kyleena hormonal IUDs? Both Mirena and Kyleena are very effective methods of contraception that last for up to 5 years. Mirena is 99.9% effective and Kyleena is 99.7% effective. Mirena may be used until 55 years of age if inserted when you are 45 years of age or older, whereas Kyleena needs to be replaced every 5 years for all ages.
  • Sterilization As a Family Planning Method

    Sterilization As a Family Planning Method

    December 2018 | Fact Sheet Sterilization as a Family Planning Method Sterilization is a permanent method of contraception, and is the most commonly used form of family planning among couples both in the United States and worldwide. For men and women who no longer want to have children, sterilization offers a permanent, safe, cost-effective and efficacious way to prevent unintended pregnancy. Male sterilization is less common than female sterilization, but both are nearly 100% effective at preventing pregnancy. The Affordable Care Act’s no-cost coverage of sterilization has increased the affordability of the procedure for women, but it is still unclear the overall effect this will have on future utilization rates. Recent changes to insurance coverage policy, broader availability of long- acting contraceptives, as well as changes in the health care delivery system may reshape the choices that men and women make regarding the use of sterilization as a contraceptive method. This fact sheet explains the types of sterilization procedures available to women and men, reviews private insurance and Medicaid coverage policy, and discusses issues that affect availability in the U.S. Female Sterilization Female sterilization is an Figure 1 outpatient surgical Prevalence of Sterilization Among Women 15 to 44 Who procedure. The procedure Report Using a Reversible or Permanent Contraceptive blocks the fallopian tubes, Method, 2013-2015, by Selected Characteristics preventing eggs from All women, ages 15-44 22% travelling down the tubes to the uterus and blocking Ages 25-34 19% sperm from fertilizing the Ages 35-44 39% egg. Data from the Centers for Disease Control and Black 26% Hispanic 25% Prevention (CDC) show that White 21% among women ages 15 to 44 who use a contraceptive ≥ 200% FPL 16% method, one in five used ≤ 200% FPL 29% tubal ligation as their method 1 of contraception.
  • The Clinical and Haematological Effects of Hormonal Contraception on Women with Sickle Cell Disease

    The Clinical and Haematological Effects of Hormonal Contraception on Women with Sickle Cell Disease

    THE CLINICAL AND HAEMATOLOGICAL EFFECTS OF HORMONAL CONTRACEPTION ON WOMEN WITH SICKLE CELL DISEASE Asma Adam Eissa Institute for Women’s Health University College London Submitted in accordance with the requirements of University College London for the degree of MD (Research) 2013 I, Asma Adam Eissa, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 ABSTRACT Sickle cell disease (SCD) is known to be a prothrombotic condition; this is also true for combined hormonal contraceptives (HC), which increases the thrombotic risks in their users. Recently, Sickle Cell Trait (SCT) has been reported to carry increased risks of thrombosis Nonetheless, HC methods are efficacious and widely used while, pregnancy carries major risks for SCD women. Hence, there is a need for robust evidence about the safety or risks of HC in SCD and SCT to aid in the choice of contraceptive methods for these women. This study aimed to test the hypothesis that there are no additional clinical or haematological risks to SCD patients and women with SCT using hormonal contraceptive methods that is over and above those inherent in their SCD and SCT status. This is a multi-centre, prospective cohort study, which looked at and compared clinical complications, haemostatic and haematological markers in 68 women with SCD, 22 women with SCT and 27 similar women with normal haemoglobin. In conclusion a two year follow-up of women with SCD using Combined Oral Contraception (COC) found no incidence of Venous Thrombo Embolism (VTE) in these women and the occurrence of other clinical complications, such as sickle-cell crises, the need for blood transfusion and hospital admissions were minimal.
  • Sterilization of the Developmentally Disabled: Shedding Some Myth-Conceptions

    Sterilization of the Developmentally Disabled: Shedding Some Myth-Conceptions

    Florida State University Law Review Volume 9 Issue 4 Article 3 Fall 1981 Sterilization of the Developmentally Disabled: Shedding Some Myth-Conceptions Deborah Hardin Ross Follow this and additional works at: https://ir.law.fsu.edu/lr Part of the Disability Law Commons, Health Law and Policy Commons, Human Rights Law Commons, and the Law and Society Commons Recommended Citation Deborah H. Ross, Sterilization of the Developmentally Disabled: Shedding Some Myth-Conceptions, 9 Fla. St. U. L. Rev. 599 (1981) . https://ir.law.fsu.edu/lr/vol9/iss4/3 This Comment is brought to you for free and open access by Scholarship Repository. It has been accepted for inclusion in Florida State University Law Review by an authorized editor of Scholarship Repository. For more information, please contact [email protected]. STERILIZATION OF THE DEVELOPMENTALLY DISABLED:* SHEDDING SOME MYTH-CONCEPTIONS DEBORAH HARDIN Ross I. Introduction ..................................... 600 II. Non-Consensual Sterilization Under Statutory Au- thority .......................................... 602 A. Sociological, Legislative, and Judicial Back- ground ..................................... 602 B. Analysis of Present Statutes .................. 606 1. To Whom Applied ...................... 607 2. Procedure .............................. 607 3. Justification for Sterilization ............. 608 4. Standards .............................. 609 C. Substantive Due Process ..................... 609 1. No Compelling State Interest ............ 611 a. Justifications and False Assumptions
  • Extended USE of LARC METHODS

    Extended USE of LARC METHODS

    y EXTENDEd USE OF COVID-19 RESPONSE LARC METHODS Overview There is research data that supports extended use for most methods of long-acting reversible contraception (LARC) available in the United States. Studies have concluded that some hormonal IUDs (Mirena, Liletta), as well as the copper IUD (Paragard) and the contraceptive implant (Nexplanon), are effective beyond their FDA-approved duration. For each LARC method, presented below is the current duration of use as approved by the FDA, as well as links to research that shows the efficacy of use past their FDA-approved duration. When counseling a patient on extended use, inform them of both the FDA-approved duration and the evidence-based duration, and explain why the official label may not represent the most up-to-date research findings. Patients can make the choice for themselves about extending use of their LARC device, particularly in times when a visit to a provider is difficult. Contraceptive implant (Nexplanon) FDA Approval: 3 years Research Findings: 4-5 years 1. Ali M, Bahamondes L, Landoulsi SB. Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling. GlobalHealth: Science and Practice. 2017;5(4):534-539. doi:10.9745/ghsp-d-17-00296. 2. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration. American Journal of Obstetrics and Gynecology. 2017;216(6):586.e1-586.e6. doi:10.1016/j.ajog.2017.01.036.